article thumbnail

Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research

NORML

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. Dr. Sue Sisley. Later that night, everyone celebrated at a hotel bar.

DEA 230
article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.

DEA 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Is Congress Closer to Reforming the Cannabis Industry’s Access to Financial Services?

Veriheal

Historically, it has been difficult for cannabis-related businesses to access reliable financial services due to its illegal federal status. This bill also directs the DEA to register manufacturers and distributors of CBD or marijuana for commercial production of an approved drug that contains marijuana or its derivative.

Access 108
article thumbnail

U.S. Federal Court Tells DEA to Evaluate Rescheduling Cannabis, in Light of its Medical Benefits

WeedAdvisor

In a rather surprising turn of events, a federal appeals court gave marijuana advocates a small opening in their ongoing battle to reschedule marijuana, according to Marijuana Moment. The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA.

DEA 55
article thumbnail

Psychedelics Activists Protest Outside DEA’s Offices – Arrests Made

Cannabis Law Report

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. DeaOutoftheway @RTTpsilocybin pic.twitter.com/1NJWt2cJWn. — Adam Eidinger ??????????????????????????????????

DEA 52
article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin. The Summit found that cannabis does not enhance athletic performance.

article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52